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1. INTRODUCTION  
Epilepsy is a common neurological disorder affecting 
approx. 0.5-1% population in all over the world. There 
are several formulations in the market those are 
employed for the treatment of epilepsy. Antiepileptic 
drug after oral or intravenous administration exhibits 
high distribution of drug into brain and other non-
targeted organs which can precipitate the undesirable 
side effects e.g. somnolence, dizziness and ataxia to 
severe peripheral pathologic conditions like 
dermatologic and hematologic, renal and hepatic 
dysfunctions.
1,2,3
The prevention of such kind of 
condition is very difficult but a much needed work, for 
this the drug should be targeted directly into the brain. 
But to deliver the drugs directly into the brain is a very 
difficult task because the penetration of drugs into brain 
is a great challenge, due to the functionality and 
structure of the BBB. The blood brain barrier is a unique 
system of capillary endothelial cell which prevent 
foreign material to permeate into the brain. BBB limits 
the transport of drugs by tight junction or physical 
barrier and the transendothelial electron resistance 
(TEER), enzymes or metabolic barrier also limits the 
penetration into brain.
4
 In last 10 years, different 
techniques have been attempted to target the brain to 
deliver drugs directly into the brain. Nowadays 
alternative route of drug delivery is in practice, nasal 
route has attracted scientist’s attention to develop new 
drug delivery system.
5
 Nasal route appears to be an ideal 
alternative to parenterals for systemic drug delivery as 
well as for brain tageting.
6
 Nasal drug delivery is a non-
invasive method and it also avoids gastrointestinal and 
hepatic first-pass metabolism. It exhibit rapid-onset of 
action, patient compliance, self administrable, which 
make it a route of choice for the management of 
emergency situations.
7
 Despite these advantage nasal 
drugs delivery has some limitations for drug penetration 
like size, molecular weight and low residence time of 
drugs in the nasal cavity.
4,7 
To overcome these problems 
particulate carrier like nanoparticles made up of 
mucoadhesive biomaterial can be used to target brain via 
nasal route due to their small size and mucoadhesive 
properties.
8
 Polymeric nanoparticles are solid colloids 
having a size of 10-1000nm. Chitosan is widely used 
polymer for preparation of mucoadhesive nanoparticles. 
Chitosan shows very good entrapment of drugs. Various 
studies have shown the successful use of chitosan 
nanoparticles for better drug targeting in brain as well as 
systemic circulation.
8
   
Carbamazepine is first-line antiepileptic drugs with 
narrow therapeutic window, complex pharmacokinetics, 
it has chances of interacting with other drugs and 
causing side effects,  it is  absorbed slowly from the oral 
route, its oral bioavailability is 75% and the peak plasma 
concentration is achieved in about 4-8h after dosing, it 
may be vary to 24h at  high doses.
2 
Carbamazepine 
metabolized by liver and the enzymatic induction can 
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cause the unpredictable fluctuation in plasma and an 
increase in unexpected clearance. For this the dose 
adjustment is required. All these pharmacokinetics 
limitation of orally administered carbamazepine make it, 
a suitable candidate for making nanoparticles using 
chitosan polymer for nasal administration. 
 
2 MATERIALS AND METHOD 
2.1 Material  
Chitosan was obtained as a gift sample from CIFT, 
Kocchi, and Carbamazepine was purchased from Sigma 
Alderich Mumbai, Tween80 was purchased from 
Central Drug House, Mumbai, Dialysis membrane-70 
was purchased from Hi Media, Mumbai. All other 
chemicals and solvents used in the study were of 
analytical or HPLC grade. 
2.2 Method 
Nanoparticles were prepared by using ionic gelatin 
technique, which was described by Calvo,
11
 in which 
100-300mg chitosan was dissolved in 100ml aq. 
solution of 0.5% acetic acid.
 
The aq. solution of 100-
300mg TPP sod was prepared separately. Then the 
required amount of drug was dissolved in 10ml 
methanol and mixed into chitosan solution. Then 25ml 
of the aq. solution of TPP sod was added to 100ml of 
chitosan solution and stirred for 2hr at 4000rpm using 
Remi mechanical stirrer. The formed nanoparticles were 
collected by centrifuging the system for 10min at 
5000rpm and then air dried. Nine formulations were 
prepared by varying chitosan and TPP sod conc.  
2.2.1 Particle size: 
The average diameter and Polydispersity Index (PDI) of 
prepared batches of carbamazepine loaded chitosan 
nanoparticles were determined by Photon Correlation 
Spectroscopy (PCS) using a Zetasizer (Malvern, Ver. 
6.01) at a fixed angle at 25°C. Sample was diluted 10 
times with distilled water and then it was analyzed for 
particle size. The readings were recorded in triplicate. 
2. 2.2 Zeta potential: 
The zeta potential can be measured by determination of 
the movement velocity of the particles in an electric 
field and the particle charge, the chitosan nanoparticles 
dispersion was diluted 10 times with distilled water and 
analyzed by Zetasizer (Malvern, Ver. 6.01).  
2.2.3 Drug Entrapment Efficiency  
The entrapment efficiency (EE), which corresponds to 
the percentage of carbamazepine encapsulated within 
and adsorbed on to the nanoparticles, was determined by 
measuring the concentration of free carbamazepine in 
the dispersion medium. 10 mg of carbamazepine loaded 
nanoparticles was dissolved into 10ml methanol and 
kept for overnight then centrifuged at 5000rpm for 
10min. Supernatant was than filtered by 0.2µ membrane 
filter and analyzed by UV-VIS spectroscopy at 280.4 
nm.  
    % EE =    [Initial drug – Free drug] x 100         eq.1 
  Initial drug 
Where, Initial drug is the mass of initial drug used for 
the assay. 
Free drug is the mass of free drug detected in the 
supernatant after centrifugation of the aqueous 
dispersion. 
2.2.4 Drug Content 
10mg of carbamazepine nanoparticles was dissolved 
into 10ml methanol and kept for overnight. The soaked 
solution was centrifuged at 5000 rpm for 10min to 
separate the polymer. Supernatant was than filtered by 
0.2µ membrane filter and analyzed by UV-VIS 
spectroscopy at 280.4 nm. 
2.2.5 In-Vitro Drug Release Study nanoparticles
12 
The in-vitro release study was performed using 
previously overnight soaked dialysis membrane-70 
mounted over the receptor compartment of Franz 
diffusion cell. The donor compartment was fixed and 
37°C±0.5°C and stirred at 100rpm with Teflon-coated 
magnetic stirring bars. The formulations were placed in 
donor compartment and dialysis medium (buffer pH 5.5) 
was filled in receptor compartment. At predetermined 
time intervals (0.5, 1, 2, 3, for 9 hrs.), 5 ml aliquots was 
withdrawn and replaced with the same amount of fresh 
medium. Sink condition was maintained throughout the 
experiment. The amount of carbamazepine released 
from the nanoparticles was measured by UV 
spectrophotometer at 280.4 nm. 
2.2.6 In-Vitro Drug Release Kinetics
13, 14 
In order to investigate the mechanism of release, the 
release data were analyzed with the following 
mathematical models: zero-order kinetic, first-order 
kinetic, Korsmeyer-Peppas kinetic model and Higuchi 
kinetic model. 
2.2.7 Pharmacokinetic studies
1
 
The rats were divided into two groups (A and B), Group 
A containing 18 animals which received the drug by i.v. 
administration and group B containing 18 animals 
received nanoparticles by nasal route. At a set time 
interval (5, 15,30,45,60,120 min) after dosing 3 animal 
per time point were sacrificed by cervical dislocation 
then decapitated. The blood was then immediately 
collected in tube containing heparin. The brain was 
removed and weighed. The blood sample were 
centrifuged at 4
0
C at 4000rpm for 10min. the plasma 
were stored at -30 0 C for further analysis. The brain 
was homogenized with 0.1M sod phosphate buffer 
pH5.0 (4ml per gram) of tissue. The Teflon pestle tissue 
homogenizer was used. Tissue homogenate was then 
centrifuged at 4000rpm for 15min at 4
0
C and the 
supernatant was then kept at -30 0 C for further analysis.        
2.2.8 In-vivo experiments in rat 
The in-vivo experiments were performed on Wistar rat at 
Deshpande Lab Bhopal, India. All animal studies were 
performed according to CPCSEA. The CPCSEA/IAEC 
approval No. IAEC /DL/ 2015/RK/012. 
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2.2.9 Preparation of IV Drug solution for i.v. 
Administration
1
 
For i.v. administration, the drug was dissolved in a 
mixture of propylene glycol-physiologic saline 
(0.9%NaCl)-ethanol in a ratio of 5:3:2 to make a final 
conc. of 1mg per ml.   
2.2.10 Intranasal and i.v. administration
1
 
The rats were anaesthetized with an intraperitoneal 
injection of a mixture of ketamine (100mg/ kg) and 
xylazine (10mg/kg) and the temperature of room was 
maintained warm. The prepared i.v. solution at dose of 
0.1mg/kg was administered by injection on lateral tail 
vein. The prepared nanoparticles were administered at a 
dose equivalent to 1mg/kg to rat. The rat was placed on 
one side and the formulation was instilled using a 
polyurethane tube attached to a syringe. The tube 
inserted to 10mm deep into one the nares, to deliver the 
formulation to roof of the nasal cavity. 
2.2.11 Drug Analysis:  
Determination of drug was performed by a liquid 
chromatography system equipped with DAD detector 
1100 at 285 nm (Agilent Technologies, Milano, Italy). A 
Luna® phenyl hexyl 5-m (Phenomenex, Torrance, 
USA) 250mm×4.6mm column with cartridge precolumn 
was used for separation at a flow rate of 0.60 ml/min. 
The mobile phase consisted of acetonitrile, methanol 
and water (0.1%) 30:60:10 (v/v) and the injection 
volume was 100µl. The amount of carbamazepine in 
serum and brain was expressed as ng/ml serum. 
2.2.12 Pharmacokinetic analysis
13
 
The peak plasma conc. Cmax of drug was directly 
observed from plasma or brain and the time (Tmax) to 
reach Cmax was directly estimated from the data received 
by experiments, other Pharmacokinetic parameter were 
calculated based on the SEM (n=3) at each time point by 
a non compartment pharmacokinetics analysis. The 
pharmacokinetics parameters like AUC were evaluated, 
from t0 to the last quantifiable conc. tlast by linear 
trapezoidal rule. 
To assess the brain targeting efficiency of nasal 
formulations the drug targeting efficiency (DTE) index 
was calculated. It is a ratio of nasal and i.v. 
      (eq. 2) 
Where AUCbrain and AUCplasma are the area under the 
drug conc. time curve for brain and plasma after nasal 
and i.v. administration. For an effective drug targeting 
the ratio should be more than one. 
2.2.13 Statistical analysis 
The data were expressed as SEM, the comparative 
studies done between i.v. and nasally delivered  
formulation using single unpaired one tail ANOVA, 
difference was considered significant for a p- value 
p<0.05.  
3. RESULT AND DISCUSSION 
3.1 Preparation of Chitosan Nanoparticles  
In present study, ionic gelation method was used to 
prepare nanoparticles, a simple and reproducible method 
for preparation of polymeric nanoparticles  
3.2. Characterization of Chitosan Nanoparticles: 
3.2.1 Particle Size: 
In all the formulations, the particles size ranged from 
124.2±05 to 580±13nm, and polydispersibility index 
were found to be 0.261±0.15 to 0.656±0.073. The 
results are given in table no.1. The study reveals that, 
polymer conc. have a significant effect on size, at the 
lower conc. of polymer, small size nanoparticles 
formed, but on increasing the conc. of polymer the size 
of nanoparticles increased, at higher conc. the chitosan 
forms a viscous gel which would not break down into 
small particles at given stirring speed, therefore a high 
particle size was observed. The conc. of sod TPP also 
plays effective role in size controlling, as the conc. of 
TPP sod was increased the particles size was decreased.  
3.2.2 Zeta Potential 
In all the formulations, the zeta potential ranged from 
+32.1 to +15.1. The chitosan is positively charged 
polymer therefore as the conc. of chitosan increased the 
zeta potential increases, and because the TPP sod is 
negatively charged therefore on increasing the conc. of 
TPP sod the zeta potential decreased. The results are 
given in table no.1   
The higher zeta potential shows that  all formulation are 
stable because the high zeta potential would not allow 
the particles to get aggregate or to form a big colloid due 
to electrical repulsion between particles. The Tween-80 
would also provide stabilization to the formulations. The 
final results are shown in table no.1 
 
Arya et al                                   Journal of Drug Delivery & Therapeutics. 2015; 5(3):101-108 104 
© 2011-15, JDDT. All Rights Reserved                                      ISSN: 2250-1177                                    CODEN (USA): JDDTAO 
 
Figure 1: showing particle size of formulation Ch1    
 
Figure 2: showing zeta potential of formulation Ch1 
 
3.2.3 Drug Entrapment Efficiency  
Percentage entrapment efficiency of all the formulations 
was found to be 40±1.25 to 69±0.85. The results are 
given in table no.1 
The results shows that the polymer conc. play an 
important role in drug entrapment, on increasing the 
conc. of chitosan initially favors increase in the 
entrapment efficiency up to a certain level and then a 
decrease in the entrapment efficiency was observed may 
be due to the formation of viscous gel at higher polymer 
conc. i.e. 0.3%, the gel might hinder the permeation of 
drug into chitosan polymer matrix during formation of 
nanoparticles.  
 The conc. of TPP sod also affects the entrapment 
efficiency, at higher conc. of TPP sod the entrapment 
efficiency also decreased due to formation of a cross 
linked network which would not allow the drug to get 
diffuse into the polymer-TPP network.  
3.2.4 Drug Content 
Percentage drug content of all the formulation was found 
to be 84.69% to 98.85%. The final results are shown in 
table no.1 
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Table 1: 
S.NO. Batch code Zeta size (nm) PDI Zeta potential 
(mV) 
% EE %Drug 
content 
1 Ch1 124.2±05  0.368±0.12 +25.4 65±0.12 84.69% 
2 Ch2 370±07 0.258±0.154 +28.9 69±1.02 98.85%. 
3 Ch3 580±13  0.431±0.09 +32.1 56±0.98 88.34% 
4 Ch4 108±10  0.368±0.65 +17.2 58±0.56 88.25% 
5 Ch5 310±05  0.261±0.15 +19.2 61±0.80 86.05% 
6 Ch6 410±09 0.461±0.106 +20.1 51±1.07  85.85% 
7 Ch7 89±03 0.638±0.170 +15.1 48±1.10 90.85% 
8 Ch8 250±10 0.656±0.073 +17.5 53±0.85 92.85% 
9 Ch9 325±12 0.361±0.08 +19.8 40±1.25 91.85% 
 
3.2.5. In-vitro drug release 
The in-vitro cumulative drug release was found to be 
69.8% to 82.8%. The formulation Ch2 shows the highest 
drug release in 9hr i.e. 86.3% where as Ch9 shows the 
lowest drug release i.e. 69.8 % in 9hr. it was observed in 
the study that the conc. of chitosan and the conc. of TPP 
sod plays important role in drug release from the 
formulations. Initially in the first 120min the drug 
released highest from the Ch3 having the highest conc. 
of chitosan but after 120 min the release is retarded 
because its forms gel, which retarded the drug release. 
On the other hand the increase in TPP sod conc. also 
retarded drug release because higher conc. of TPP sod 
makes a close network within the chitosan polymeric 
network.  
3.2.5.1. Effect of chitosan conc. on drug release  
Statistical analysis was used to analyze and check, 
whether there was any significant difference present in 
drug release pattern of different formulations or not. 
The single factor ANOVA was done with the help of 
MS Excel 2007 Software for a time period of 9hr 
applied for drug release, with increase in conc. of 
chitosan, a significant decrease p<0.05 (0.009335) was 
observed in in-vitro release of carbamazepine from 
nanoparticles, as the conc. of chitosan increased from 
0.1% to 0.2% the drug release increased from 82.8 % to 
86.3 but on increasing the conc. of chitosan to 0.3% 
from 0.2% the drug release was decreased. 
 
 
Figure 3: showing In-vitro drug release of formulation Ch1, Ch2, Ch3 and Ch9 
 
In first 2hr, formulation Ch3 has higher chitosan conc. 
shows faster release about 31.3% than Ch1 and Ch2 but 
the drug release then decreased in comparison to Ch1 
and Ch2.  This is may be due to the formation of gel at 
higher chitosan conc. 
3.2.5.2. Effect of cross linking agent 
To understand the effect of cross linking agent on the 
drug release, formulation Ch1,Ch2 and Ch3 were 
analyzed with increasing conc. of TPP sod  a significant 
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p<0.05 (0.006163) decrease in release rate was observed 
which revealed that the higher conc. of cross linking 
agent retards the drug release. The 80.7%, 84.23% and 
86.51% carbamazepine was released from Ch1, Ch2 and 
Ch3 respectively. 
3.2.6. Kinetics modeling of all formulation 
The drug release kinetics of all formulations was 
evaluated to understand the drug release behavior from 
the chitosan nanoparticles. The drug release data were 
evaluated for a best fit equation of Zero order, First 
order, Koresymer Papas and Higuchi model.  From the 
above study, the drug release data of most of the 
formulations fits into Korsmeyer Papps model where r
2
 
value were found near to 0.999, for the drug release of 
formulations Ch1, Ch2, Ch3, Ch4, Ch6 and Ch9. The 
formulations Ch5, Ch7, and Ch8 have shown a zero 
order drug release. But the drug release data of 
formulation Ch1 has shown a perfect Korsmeyer Papps 
model where the r
2
 value was found to be 0.9904 and the 
K value was found to be 0.6059, which shows that the 
drug release follows Korsmeyer Papps model with non-
Fickian diffusion super class II (0.45 < n< 0 8.9). The 
drug release from the chitosan nanoparticles may be due 
to the diffusion of water into the nanoparticles followed 
by swelling and finally formation of gel. The non-
fickian case-II transport mechanism associated with 
formation of water soluble glassy polymer. The first 
60% drug release data fits into Korsmeyer Papps from 
the above studies formulation Ch1 is selected for further 
study because it has narrow size range 124.2nm with 
good entrapment efficiency 65% and a good release 
profile. In this formulation the drug release initially 
showed a burst release and then a constant release for a 
period of 9hr.  
3.2.7. Transmission Electron Microscopy: 
The TEM study of the optimized formulation Ch1 was 
done, which also confirms the size of the prepared 
nanoparticles. 
 
 
Figure 4: Showing TEM photograph (A) of Formulation Ch1 and B showing single particle of Formulation Ch1 
 
3.2.8. Pharmacokinetics study of drug from i.v. and 
nasally applied chitosan nanoparticles Ch1 
The pharmacokinetic data from i.v. administration, the 
Cmax and Tmax in plasma and brain was directly 
determined, in first 5min the Cmax was achieved in 
plasma but in brain it has taken 30min to achieve Cmax. 
The AUC in plasma and brain was calculated by 
trapezoidal method, the i.v. AUC(Plasma)0-120min was 
found to be 110.51 µgml
-1
 min
-1 
and AUC(Brain)0-120min
 
was found to be 78.95 µgml
-1
 min
-1
. The Cmax in plasma 
1199ng and brain was found to be 1357ng. The ratio of 
AUC(Brain) and AUC(Plasma) was found as 0.7144, 
which shows, the distribution of drug into brain (targets) 
and plasma (non target) slightly equal. The study reveals 
that the conc. in plasma is initially higher, this higher 
conc. can precipitate the side effects, after some time the 
conc. was found higher in brain than plasma. 
Then the formulation Ch1 was given nasally to Wister 
rat after a single dose of drug 1mg/kg, the corresponding 
pharmacokinetic parameter estimated by non-
compartmental analysis and AUC was calculated by 
trapezoidal method, initial conc. was extrapolated to the 
origin. In first 5min the Cmax was achieved in brain but 
in plasma it has taken 45min to achieve Cmax. The AUC 
(Plasma) 0-120min was found to be 104.43 µgml
-1
 min
-1 
and 
AUC (Brain) 0-120min
 
was found to be 129.53 µgml
-1
 min
-
1
. The Cmax in plasma 1430ng and brain was found to be 
2920ng. The ratio of AUC (Brain) and AUC(Plasma) 
was found as 1.240, which shows, the high distribution 
into brain than plasma can be achieved with chitosan 
nanoparticles. 
The drug transport efficiency was found to be 1.735, 
which shows that a chitosan nanoparticle has good brain 
targeting efficiency. 
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Figure 5: showing plasma and brain concentration- time profile of carbamazepine after i.v and nasally applied  
nanoparticles, The results are mean values ± SEM, n=3, † represents significant difference at any time point. 
Table 2: Showing Pharmacokinetic parameters in brain and plasma after nasal and i.v. administration 
Route Organ/tissue CMax TMax AUC 0-120min
 
i.v. Plasma 1199ng 5min 110.51 µgml
-1
 min
-1    
 
Brain
 
1357ng 30min 78.95 µgml
-1
 min
-1
 
Nasal
 Plasma
 
1430ng  45min 104.43 µgml
-1
 min
-1    
 
Brain
 
2920ng 5min 129.53 µgml
-1
 min
-1
 
AUC (Brain) /AUC(Plasma) nasal 1.240  
AUC (Brain) /AUC (Plasma) i v
 0.7144 
DTE 1.735 
 
SUMMARY AND CONCLUSION 
The chitosan nanoparticles of carbamazepine were 
successfully prepared by ionic gelation method using 
chitosan as polymer and TPP sod as ionic gelation 
agent. Nine formulations Ch1, Ch2, Ch3, Ch4, Ch5, 
Ch6, Ch7, Ch8 and Ch9 were prepared successfully. The 
conc. of chitosan and TPP sod was varied to understand 
the behavior of Chitosan and TPP sod on particle size, 
entrapment efficiency and drug release behavior. 
Formulation Ch1 has the smallest size and good 
entrapment efficiency and good in-vitro drug release 
profile therefore Ch1 selected for further in-vivo study.  
The pharmacokinetic study of Ch1 revealed that drug 
achieved Cmax in plasma in 45min and it has taken only 
5min to achieve the Cmax in brain whereas from i.v. 
route the Cmax in plasma and brain was achieved in 5min 
and 30min respectively. The drug targeting efficiency 
was found to be 1.735, From the above study it was 
concluded that chitosan nanoparticles are able to 
transport the drug from nose to brain and can release the 
drug with enhance residence time and prolong drug 
release with lowest possible side effects due to lesser 
amount of drug reaches to the systemic circulation.  
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